Appointments

Request an Appointment

Cancer Answer Line:
866.223.8100

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

View Cancer Clinical Trials

RTOG 0913   |   02-12-07C
Phase I/II Trial of Concurrent RAD001 (Everolimus) with Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma

Disease(s)
Brain
Hospital(s)
Fairview
Hillcrest
Independence
Main Campus
North Coast Cancer
Strongsville
Wooster
Phase(s)
Phase 1
Phase 2
Stage(s)
Type(s)
Therapeutic
Drug(s)
RAD-001
Temozolomide (SCH 52365)

Contact Information
Cancer Answer Line

866.223.8100

8:00 am - 4:30 pm, Monday - Friday


Description
Phase I
  1. Primary
    • To define the maximum tolerated dose of RAD001 (up to established dose of 10 mg/day) when combined with concurrent radiation and temozolomide in newly diagnosed GBM.
  2. Secondary
    • To characterize the safety profile of RAD001 in combination with radiation and temozolomide.
    Phase II
    1. Primary
      • To determine the efficacy of RAD001 in combination with radiation and temozolomide followed by RAD001 in combination with temozolomide in patients with newly diagnosed GBM as measured by progression-free survival.
    2. Secondary
      • To determine overall survival in newly diagnosed GBM treated with the study regimen.
      • To further evaluate the safety profile of RAD001 in combination with radiation and temozolomide in this patient population.
      • To determine if activation of the Akt/mTOR axis predicts response to RAD001 therapy.
      • To determine if there is an association between tumor MGMT gene methylation status and response to RAD001.

Inclusion Criteria
  • Histologically proven diagnosis of glioblastoma (WHO grade IV) confirmed by central pathology review prior to Step 2 registration. Since gliosarcoma is a variant of glioblastoma, gliosarcoma is also an eligible diagnosis.
  • Tumor tissue available for correlative studies (Required ONLY in phase II portion, as described below and in Section 10).
    • Patients must have at least 1 block of tissue; if a block cannot be submitted, two tissue specimens punched with a skin punch (2 mm diameter) from the tissue block containing the tumor may be submitted (see Section 10).
    • Diagnosis must be made by surgical excision, either partial or complete. Stereotactic biopsy or CUSA (Cavitron ultrasonic aspirator)-derived tissue is not allowed for patients on Phase II, as it will not provide sufficient tissue for the required MGMT and pAKT/pMTOR analyses.
  • The tumor must have a supratentorial component
  • Patients must have recovered from the effects of surgery, postoperative infection, and other complications.
  • A diagnostic contrast-enhanced MRI or CT scan (if MRI is not available due to non-compatible devices) of the brain must be performed preoperatively and postoperatively. The postoperative scan must be done within 28 days prior to step 2 registration, ,preferably within 96 hours of surgery. Preoperative and postoperative scans must be the same type.
    • Patients unable to undergo MR imaging because of non-compatible devices can be enrolled, provided pre- and post-operative contrast enhanced CT scans are obtained and are of sufficient quality.
  • History/physical examination within 14 days prior to step 2 registration
  • Neurologic examination within 14 days prior to step 2 registration
  • Documentation of steroid doses within 14 days prior to step 2 registration
  • Karnofsky performance status ≥ 70
  • Age ≥ 18 years
  • CBC/differential obtained within 14 days prior to step 2 registration, with adequate bone marrow function defined as follows:
    • Absolute neutrophil count (ANC) ≥ 1,800 cells/mm3;
    • Platelets ≥ 100,000 cells/mm3;
    • Hemoglobin ≥ 10.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 10.0 g/dl is acceptable.)
  • PT/INR ≤ 1.5.
    • Anticoagulation is allowed if target INR ≤ 1.5 on a stable dose of warfarin or on a stable dose of LMW heparin for > 2 weeks at the time of enrollment.
  • Adequate renal function, as defined below:
    • BUN ≤ 30 mg/dl within 14 days prior to step 2 registration
    • Serum creatinine ≤ 1.5 x ULN within 14 days prior to step 2 registration
  • Adequate hepatic function, as defined below:
    • Bilirubin ≤ 1.5 x normal range within 14 days prior to step 2 registration
    • ALT ≤ 2.5 x normal range within 14 days prior to step 2 registration
    • AST ≤ 2.5 x normal range within 14 days prior to step 2 registration
  • Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides ≤ 2.5 x ULN. NOTE: If one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication.
  • For females of child-bearing potential, negative serum pregnancy test within 14 days prior to step 2 registration
  • Women of childbearing potential and male participants must practice adequate contraception
  • Patient must provide study-specific informed consent prior to registration

Exclusion Criteria
  • Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years (For example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
  • Recurrent or multifocal malignant glioma
  • Metastases detected below the tentorium or beyond the cranial vault
  • Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment
  • Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in overlap of radiation therapy fields
  • Prior chemotherapy or radiosensitizers for cancer of the head and neck region; note that prior chemotherapy for a different cancer is allowable, except prior temozolomide or RAD001.
  • Prior radiation therapy or chemotherapy for glioblastoma
  • Severe, active co-morbidity, defined as follows:
    • Symptomatic congestive heart failure of New York heart Association Class III or IV
    • Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within the last 6 months, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease
    • Severely impaired lung function as defined as spirometry and DLCO that is 50% of the normal predicted value and/or 02 saturation that is 88% or less at rest on room air
    • Uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN
    • Active (acute or chronic) or uncontrolled severe infections requiring intravenous antibiotics
    • Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
    • Acquired immune deficiency syndrome (AIDS) based upon current CDC definition or known HIV seropositivity; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with HIV/AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
    • Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity
    • Other major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration or completion of protocol therapy
  • Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic
  • Women who are breast feeding, due to possible adverse effects on the infant
  • Prior allergic reaction to temozolomide
  • Patients who have received prior treatment with an mTOR inhibitor (e.g., sirolimus, temsirolimus, everolimus) or with a known hypersensitivity to these agents or to their excipients
  • Treatment on any other therapeutic clinical protocol
  • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
  • Concurrent use of enzyme-inducing anti-epileptic drugs (EIAEDs) (See Appendix V)
    • Patients previously receiving these agents must have discontinued their use at least 14 days prior to step 2 registration
  • History of deep vein thrombosis or pulmonary embolism.

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).

Referrals

Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2014 Cleveland Clinic. All rights reserved.